These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 7567319)

  • 21. An economic analysis of rotavirus vaccination in Italy.
    Giammanco MD; Coniglio MA; Pignato S; Giammanco G
    Vaccine; 2009 Jun; 27(29):3904-11. PubMed ID: 19446934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medicaid-based child restraint system disbursement and education and the vaccines for children program: comparative cost-effectiveness.
    Goldstein JA; Winston FK; Kallan MJ; Branas CC; Schwartz JS
    Ambul Pediatr; 2008; 8(1):58-65. PubMed ID: 18191783
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.
    Isaacman DJ; Strutton DR; Kalpas EA; Horowicz-Mehler N; Stern LS; Casciano R; Ciuryla V
    Clin Ther; 2008 Feb; 30(2):341-57. PubMed ID: 18343273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
    Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
    Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rotavirus disease burden and impact and cost-effectiveness of a rotavirus vaccination program in kenya.
    Tate JE; Rheingans RD; O'Reilly CE; Obonyo B; Burton DC; Tornheim JA; Adazu K; Jaron P; Ochieng B; Kerin T; Calhoun L; Hamel M; Laserson K; Breiman RF; Feikin DR; Mintz ED; Widdowson MA
    J Infect Dis; 2009 Nov; 200 Suppl 1():S76-84. PubMed ID: 19817618
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The economics of routine childhood hepatitis A immunization in the United States: the impact of herd immunity.
    Armstrong GL; Billah K; Rein DB; Hicks KA; Wirth KE; Bell BP
    Pediatrics; 2007 Jan; 119(1):e22-9. PubMed ID: 17200247
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rotavirus vaccination for Hong Kong children: an economic evaluation from the Hong Kong Government perspective.
    Ho AM; Nelson EA; Walker DG
    Arch Dis Child; 2008 Jan; 93(1):52-8. PubMed ID: 17855438
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potential epidemiological and economical impact of two rotavirus vaccines in Colombia.
    De la Hoz F; Alvis N; Narváez J; Cediel N; Gamboa O; Velandia M
    Vaccine; 2010 May; 28(22):3856-64. PubMed ID: 20347057
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of influenza vaccination of healthy children.
    Salo H; Kilpi T; Sintonen H; Linna M; Peltola V; Heikkinen T
    Vaccine; 2006 Jun; 24(23):4934-41. PubMed ID: 16678945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Health economics of rotavirus immunization in Vietnam: potentials for favorable cost-effectiveness in developing countries.
    Tu HA; Rozenbaum MH; Coyte PC; Li SC; Woerdenbag HJ; Postma MJ
    Vaccine; 2012 Feb; 30(8):1521-8. PubMed ID: 22119590
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness analysis of a universal rotavirus immunization program in Japan.
    Sato T; Nakagomi T; Nakagomi O
    Jpn J Infect Dis; 2011; 64(4):277-83. PubMed ID: 21788701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.
    Pinkerton SD; Holtgrave DR; Pinkerton HJ
    Arch Intern Med; 1997 Sep; 157(17):1972-80. PubMed ID: 9308509
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030.
    Atherly DE; Lewis KD; Tate J; Parashar UD; Rheingans RD
    Vaccine; 2012 Apr; 30 Suppl 1():A7-14. PubMed ID: 22520139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of rotavirus vaccination in Turkey.
    Koksal T; Akelma AZ; Koksal AO; Kutukoglu I; Ozdemir O; Yuksel CN; Bozkaya D; Catal F; Sari S
    J Microbiol Immunol Infect; 2017 Oct; 50(5):693-699. PubMed ID: 27107612
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland.
    Tilson L; Jit M; Schmitz S; Walsh C; Garvey P; McKeown P; Barry M
    Vaccine; 2011 Oct; 29(43):7463-73. PubMed ID: 21821085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness analysis of universal childhood vaccination against varicella in Brazil.
    Valentim J; Sartori AM; de Soárez PC; Amaku M; Azevedo RS; Novaes HM
    Vaccine; 2008 Nov; 26(49):6281-91. PubMed ID: 18674582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of transmission dynamics on the cost-effectiveness of rotavirus vaccination.
    Shim E; Galvani AP
    Vaccine; 2009 Jun; 27(30):4025-30. PubMed ID: 19389452
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Budget impact and cost-effectiveness of including a pentavalent rotavirus vaccine in the New Zealand childhood immunization schedule.
    Milne RJ; Grimwood K
    Value Health; 2009 Sep; 12(6):888-98. PubMed ID: 19490550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of varicella serotesting versus presumptive vaccination of school-age children and adolescents.
    Lieu TA; Finkler LJ; Sorel ME; Black SB; Shinefield HR
    Pediatrics; 1995 May; 95(5):632-8. PubMed ID: 7724297
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The cost-effectiveness of pneumococcal conjugate vaccination in Australia.
    Butler JR; McIntyre P; MacIntyre CR; Gilmour R; Howarth AL; Sander B
    Vaccine; 2004 Mar; 22(9-10):1138-49. PubMed ID: 15003641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.